반고형 제제 수탁제조 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 제품 유형별, 최종 용도별, 기업 규모별, 지역별 및 부문별 예측(2026-2033년)

Semi-solid Dosage Contract Manufacturing Market Summary

The global semi-solid dosage contract manufacturing market size was estimated at USD 21.21 billion in 2025, and is projected to reach USD 50.36 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The rising demand for dermatological drug formulations, shifting outsourcing trends, and the growing need for patient-friendly medications, coupled with the prevalence of chronic diseases such as skin diseases, arthritis, and pain management, are driving the market.

Besides, the growing demand for manufacturing outsourcing, due to cost-effectiveness, is expected to drive the market growth. Furthermore, regulatory compliance and quality assurance, as well as technological advancements, including innovation in formulation technologies, are expected to boost market growth over the forecast period. Besides, most pharmaceutical companies are focusing on their core functions, such as drug discovery and commercialization, which has led contract manufacturing organizations (CMOs) to become vital partners in the development, scale-up, and commercial production of semi-solid dosages.

Semi-solid dosage forms, such as creams, ointments, gels, and lotions, have gained increased attention as a key formulation segment due to their capacity for targeted, localized therapy and high patient compliance. These forms are particularly beneficial in dermatology and pain management, as direct application to the affected area allows for a faster onset of action, reduced systemic exposure, and improved safety profiles. In addition, commercially, their non-invasive nature and ease of use make them ideal for chronic treatment, further contributing to market growth.

Moreover, the increasing global burden of skin diseases is expected to drive the market growth, with over 1.8 billion individuals affected by more than 3,000 skin conditions, making dermatological disorders a top contributor to the global disease burden. In addition, the rising prevalence of arthritis affecting more than 350 million people worldwide and the expanding elderly population are further promoting the use of topical analgesics and anti-inflammatory formulations. These products are valued for reducing the gastrointestinal risks commonly associated with oral therapies.

In addition, technological advancements are expected to drive the market due to growing advancements in formulation science, such as nanoemulsions, liposomal delivery systems, and permeation-enhancing technologies, which are significantly enhancing drug efficacy, stability, and patient compliance. CMOs are making substantial investments in automated manufacturing systems, continuous processing, and advanced mixing and homogenization equipment to ensure consistent batch quality, regulatory adherence, and cost-effectiveness. Furthermore, the adoption of quality-by-design (QbD) frameworks and digital monitoring tools is improving process control and reducing time-to-market.

Global Semi-solid Dosage Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global semi-solid dosage contract manufacturing market report based on type, product, end use, company size, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Topical
• Transdermal
• Oral
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Creams
• Ointments
• Gels
• Lotions
• Pastes
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Cosmeceutical Companies
• Others
• Company Size Outlook (Revenue, USD Million, 2021 - 2033)
• Large Size Companies
• Medium & Small Size Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. End Use
  • 1.2.4. Company Size
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Semi-solid Dosage Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Demand for Patient-Friendly Medications
    • 3.2.1.2. Growing Prevalence of Chronic Diseases
    • 3.2.1.3. Growing Demand of Outsourcing Services
    • 3.2.1.4. Regulatory Compliance
    • 3.2.1.5. Technological Advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality control challenges
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Semi-solid Dosage Contract Manufacturing Market: Type Estimates & Trend Analysis

• 4.1. Semi-solid Dosage Contract Manufacturing Market, By Type: Segment Dashboard
• 4.2. Semi-solid Dosage Contract Manufacturing Market, By Type: Movement Analysis
• 4.3. Semi-solid Dosage Contract Manufacturing Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. Topical
  • 4.4.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Transdermal
  • 4.5.1. Transdermal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Oral
  • 4.6.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Semi-solid Dosage Contract Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Semi-solid Dosage Contract Manufacturing Market, By Product: Segment Dashboard
• 5.2. Semi-solid Dosage Contract Manufacturing Market, By Product: Movement Analysis
• 5.3. Semi-solid Dosage Contract Manufacturing Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 5.4. Creams
  • 5.4.1. Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Ointments
  • 5.5.1. Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Gels
  • 5.6.1. Gels Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Lotions
  • 5.7.1. Lotions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Pastes
  • 5.8.1. Pastes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Semi-solid Dosage Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Semi-solid Dosage Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Semi-solid Dosage Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Semi-solid Dosage Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Cosmeceutical Companies
  • 6.5.1. Cosmeceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Semi-solid Dosage Contract Manufacturing Market: Company Size Estimates & Trend Analysis

• 7.1. Semi-solid Dosage Contract Manufacturing Market, By Company Size: Segment Dashboard
• 7.2. Semi-solid Dosage Contract Manufacturing Market, By Company Size: Movement Analysis
• 7.3. Semi-solid Dosage Contract Manufacturing Market Estimates & Forecasts, By Company Size, 2021 - 2033 (USD Million)
• 7.4. Large Size Companies
  • 7.4.1. Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Medium & Small Size Companies
  • 7.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Semi-solid Dosage Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Lonza Group Ltd.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Lubrizol Life Science
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Cambrex Corporation
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Contract Pharmaceuticals Limited
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Bora Pharmaceutical CDMO
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Ascendia Pharmaceuticals
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Pierre Fabre group
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Piramal Pharma Solutions
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. DPT Laboratories, LTD
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. MedPharm Ltd
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Catalent, Inc.
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Recipharm AB
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Aenova Group
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Almac Group
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Ajinomoto Bio-Pharma Services
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives